Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy

Table 3 Univariable and multivariable analyses of survival outcomes after third-line chemotherapy

	Univariable			Multivariable
	HR	95%CI	P value	HR	95%CI	P value
Sex (female)	1.39	1.0-2.0	0.062
Age	1.00	1.0-1.0	0.621
Initial stage (locally advanced)	1.15	0.8-1.8	0.511
Intermediate PS at third-line CTx (good PS)	2.22	1.4-3.6	0.001	2.46	1.5-4.1	0.001
CA19-9 (U/mL)
Initial	1.00	1.0-1.0	0.596
≥ 1000 U/mL before third-line CTx (< 1000 U/mL)	1.53	1.0-2.2	0.030	1.58	1.1-2.4	0.028
CTx regimen
Third-line CTx (TS-1)	1.07	1.0-1.2	0.253
Duration of the second-line CTx
< 19 weeks (≥ 19 weeks)	1.75	1.2-2.5	0.003	1.50	1.0-2.2	0.037
Metastases
Liver metastases before third-line CTx (no liver metastases)	1.26	0.8-1.9	0.267
Peritoneal seeding before third-line CTx (no peritoneal seeding)	1.42	1.0-2.0	0.047	1.48	1.0-2.2	0.046

PS: Performance status; TS-1: Titanium silicate-1; CI: Confidence interval; CA19-9: Carbohydrate antigen 19-9; HR: Hazard ratio; CTx: Chemotherapy.